Skip to main content

Table 1 Result of blood and urine tests performed before R-CHOP therapy

From: Successful treatment by on-demand glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in patients with diffuse large B-cell lymphoma: a case report

Parameter Value Unit Reference value Parameter Value Unit Reference value Parameter Value Unit Reference value
Blood cell count Biochemistry Immunology
WBC 4720 × 103/μL   TP 9.0 mg/dL 6.5–8.2 CRP 0.79 mg/dL < 0.30
St 0 % 0.0–19.0 Alb 3.6 mg/dL 3.7–5.5 IgG 2532 mg/dL 820–1740
Seg 89 % 27.0–72.0 α1 3.6 % 1.7–2.9 IgA 457 mg/dL 90–4000
Ly 6 % 18.0–50.0 α2 10.5 % 5.7–9.5 IgM 96 mg/dL 31–200
Mo 5 % 1.0–8.0 β 10.0 % 7.2–11.1 HBsAb (−)   (−)
Eo 0 % 0.0–7.0 γ 29.5 % 10.2–20.4 HBcAb (−)   (−)
Ba 0 % 0.0–2.0 BUN 13 mg/ dl 8.0–20.0 HBV-DNA (−)   (−)
RBC 5 ×106/μL 4.38–5.77 Cre 1 mg/ dl 0.65–1.09 HCV Ab (+)   (−)
Hb 15 g/dL 13.6–18.3 T-bil 0.4 mg/dL 0.3–1.2 HCV-RNA 2.0 LIU/ mL (−)
Ht   % 40.4–51.9 D-bil 0.1 mg/dL < 0.4 HCV serotype Group2   (−)
Plt 295 ×103/μL 14.0–37.9 AST 23 U/L 10–40 HIV Ab (−)   (−)
     ALT 19 U/L 5–45 HTLV-1 Ab (−)   (−)
Coagulation LDH 211 U/L 120–245     
PT 12 sec 10.0–13.0 ALP 238 U/L 104–338 Tumor Marker
PT% 99 % 80.0–120.0 γ-GTP 104 U/L < 79 β2MG 2.5 mg/ L 0.9–1.9
PT-INR 1.01 ratio 0.90–1.13 ChE 305 U/L 245–495 sIL-2R 1753 U/ mL  
APTT 28 sec 26.0–38.0 CPK 53 U/L 50–230 SP-D 169.3 ng/ mL < 110.0
Fib 304 mg/dL 170–410         
  1. Ab antibody, Ag antigen, sIL-2R soluble IL-2 recepter, β2-MG β2-microglobulin